StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research report released on Saturday. The firm issued a sell rating on the stock.
Separately, Roth Mkm reissued a buy rating and issued a $20.00 price objective on shares of Bio-Path in a research note on Monday, July 8th.
View Our Latest Stock Report on Bio-Path
Bio-Path Trading Up 9.2 %
Bio-Path (NASDAQ:BPTH – Get Free Report) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter in the prior year, the firm earned ($10.60) EPS. Equities research analysts predict that Bio-Path will post -6.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading
- Five stocks we like better than Bio-Path
- Breakout Stocks: What They Are and How to Identify Them
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- How to Invest in the FAANG Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.